Previous studies have reported that Bcr-Abl inhibits apoptosis in CML cells through the regulation (expression and/or activation) of members of the Bcl-2 family of apoptosis modulators [22, 42, 43]. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.